112
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Chrysin ameliorates 3 nitropropinoic acid induced neurotoxicity targeting behavioural, biochemical and histological alterations

, , , , , & ORCID Icon show all
Pages 450-458 | Received 10 Apr 2019, Accepted 20 Jul 2020, Published online: 16 Sep 2020

References

  • Illarioshkin SN, Klyushnikov SA, Vigont VA, et al. Molecular [athogenesis in Huntington’s disease. Biochem Mosc. 2018;83(9):1030–1039.
  • Choudhary S, Kumar P, Malik J. Plants and phytochemicals for Huntington’s disease. Pharmacogn Rev. 2013;7(14):81–91.
  • Humbert S, Saudou F. Huntington’s disease: intracellular signaling pathways and neuronal death. J Soc Biol. 2005;199(3):247–251.
  • Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 2010;90(3):905–981.
  • McCusker EA, Loy CT. Huntington disease: the complexities of making and disclosing a clinical diagnosis after premanifest genetic testing. Tremor Other Hyperkinet Mov. 2017;7:467.
  • Danduga RCSR, Dondapati SR, Kola PK, et al. Neuroprotective activity of tetramethylpyrazine against 3-nitropropionic acid induced Huntington's disease-like symptoms in rats. Biomed Pharmacother. 2018;105:1254–1268.
  • Orozco-Ibarra M, García-Morales J, Calvo-Silva FJ, et al. Striatal mitochondria response to 3-nitropropionic acid and fish oil treatment. Nutr Neurosci. 2018;21(2):132–142.
  • Brouillet E. The 3-NP model of striatal neurodegeneration. Curr Protoc Neurosci. 2014;67(1):9.48.1–9.48.14.
  • Zheng J, Winderickx J, Franssens V, et al. A mitochondria-associated oxidative stress perspective on Huntington’s disease. Front Mol Neurosci. 2018;11:329.
  • Jodeiri Farshbaf M, Ghaedi K. Huntington's disease and mitochondria. Neurotox Res. 2017;32(3):518–529.
  • Mirandola SR, Melo DR, Saito A, et al. 3-nitropropionic acid-induced mitochondrial permeability transition: comparative study of mitochondria from different tissues and brain regions. J Neurosci Res. 2010; 88(3):630–639.
  • Huang CL, Wang KC, Yang YC, et al. Gastrodia elata alleviates mutant huntingtin aggregation through mitochondrial function and biogenesis mediation. Phytomedicine. 2018; 39:75–84.
  • Sandhir R, Mahajan N, Mehrotra A, et al. 4-hydroxy tempo improves mitochondrial and neurobehavioral deficits in experimental model of Huntington's disease. Synapse. 2015;69(3):128–138.
  • Gao Y, Chu SF, Li JP, et al. Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease. Acta Pharmacol Sin. 2015;36(3):311–322.
  • Thangarajan S, Ramachandran S, Krishnamurthy P. Chrysin exerts neuroprotective effects against 3-nitropropionic acid induced behavioral despair-Mitochondrial dysfunction and striatal apoptosis via upregulating Bcl-2 gene and downregulating Bax-Bad genes in male Wistar rats. Biomed Pharmacother. 2016;84:514–525.
  • Jaganathan SK, Mandal M. Antiproliferative effects of honey and of its polyphenols: a review. J Biomed Biotechnol. 2009;2009:830616.
  • He XL, Wang YH, Bi MG, et al. Chrysin improves cognitive deficits and brain damage induced by chronic cerebral hypoperfusion in rats. Eur J Pharmacol. 2012;680(1-3):41–48.
  • Ahmad A, Khan MM, Ishrat T, et al. Synergistic effect of selenium and melatonin on neuroprotection in cerebral ischemia in rats. Biol Trace Elem Res. 2011;139(1):81–96.
  • Izuta H, Shimazawa M, Tazawa S, et al. Protective effects of Chinese propolis and its component, Chrysin, against neuronal cell death via inhibition of mitochondrial apoptosis pathway in SH-SY5Y cells. J Agric Food Chem. 2008;56(19):8944–8953.
  • Suganya SN, Sumathi T. Effect of rutin against a mitochondrial toxin, 3-nitropropionicacid induced biochemical, behavioral and histological alterations-a pilot study on Huntington's disease model in rats. Metab Brain Dis. 2017;32(2):471–481.
  • Andrabi SS, Parvez S, Tabassum H. Progesterone induces neuroprotection following reperfusion-promoted mitochondrial dysfunction after focal cerebral ischemia in rats. Dis Model Mech. 2017;10(6):787–796.
  • Salman M, Tabassum H, Parvez S. Piperine mitigates behavioral impairments and provides neuroprotection against 3-nitropropinoic acid-induced Huntington disease-like symptoms. Nutr Neurosci. 2020;25:1–10.
  • Liu XH, Bi HY, Cao J, et al. Early constraint-induced movement therapy affects behavior and neuronal plasticity in ischemia-injured rat brains. Neural Regen Res. 2019;14(5):775–782.
  • Ashafaq M, Tabassum H, Parvez S. Modulation of behavioral deficits and neurodegeneration by tannic acid in experimental stroke challenged wistar rats. Mol Neurobiol. 2017;54(8):5941–5951.
  • Chakraborty J, Singh R, Dutta D, et al. Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's disease. CNS Neurosci Ther. 2014;20(1):10–19.
  • Vishnoi S, Raisuddin S, Parvez S. Modulatory effects of an NMDAR partial agonist in MK-801-induced memory impairment. Neuroscience. 2015;311:22–33.
  • Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72(1-2):248–254.
  • Angelopoulou E, Pyrgelis ES, Piperi C. Neuroprotective potential of chrysin in Parkinson's disease: molecular mechanisms and clinical implications. Neurochem Int. 2020;132:104612
  • El Khashab IH, Abdelsalam RM, Elbrairy AI, et al. Chrysin attenuates global cerebral ischemic reperfusion injury via suppression of oxidative stress, inflammation and apoptosis. Biomed Pharmacother. 2019;112:108619
  • Bak J, Kim HJ, Kim SY, et al. Neuroprotective effect of caffeic acid phenethyl ester in 3-nitropropionic acid-induced striatal neurotoxicity. Korean J Physiol Pharmacol. 2016;20(3):279–286.
  • Ranju V, Sathiya S, Kalaivani P, et al. Memantine exerts functional recovery by improving BDNF and GDNF expression in 3-nitropropionic acid intoxicated mice. Neurosci Lett. 2015;586:1–7.
  • Jamwal S, Kumar P. L-theanine, a component of green tea prevents 3-nitropropionic acid (3-NP)-induced striatal toxicity by modulating nitric oxide pathway. Mol Neurobiol. 2017;54(3):2327–2337.
  • Kumar P, Kalonia H, Kumar A. Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofelone. Br J Pharmacol. 2011;164(2b):644–654.
  • Saydoff JA, Liu LS, Garcia RA, et al. Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease . Brain Res. 2003;994(1):44–54.
  • Brouillet E, Conde F, Beal MF, et al. Replicating Huntington’s disease phenotype in experimental animals. Prog. Neurobiol. 1999;59(5):427–468.,
  • Mehrotra A, Sandhir R. Mitochondrial cofactors in experimental Huntington's disease: behavioral, biochemical and histological evaluation. Behav Brain Res. 2014;261:345–355.
  • Del Fabbro L, Rossito Goes A, Jesse CR, et al. Chrysin protects against behavioral, cognitive and neurochemical alterations in a 6-hydroxydopamine model of Parkinson's disease. Neurosci Lett. 2019;706:158–163.
  • Ahmed MR, Shaikh MA, Haq SHIU, et al. Neuroprotective role of chrysin in attenuating loss of dopaminergic neurons and improving motor, learning and memory functions in rats. Int J Health Sci (Qassim). 2018;12(3):35–43.
  • Rodríguez-Landa JF, Hernández-López F, Cueto-Escobedo J, et al. Chrysin (5,7-dihydroxyflavone) exerts anxiolytic-like effects through GABAA receptors in a surgical menopause model in rats. Biomed Pharmacother. 2019;109:2387–2395.
  • Ghosh M, Pearse DD. The role of the serotonergic system in locomotor recovery after spinal cord injury. Front Neural Circuits. 2014;8:151.
  • Koch ET, Woodard CL, Raymond LA. Direct assessment of presynaptic modulation of cortico-striatal glutamate release in a Huntington's disease mouse model. J Neurophysiol. 2018;120(6):3077–3084.
  • Verma MK, Goel R, Nandakumar K, et al. Bilateral quinolinic acid-induced lipid peroxidation, decreased striatal monoamine levels and neurobehavioral deficits are ameliorated by GIP receptor agonist D-Ala2GIP in rat model of Huntington's disease. Eur J Pharmacol. 2018;828:31–41.
  • Bortolato M, Chen K, Shih JC. Chapter 2.4 – The degradation of serotonin: role of MAO. In: Muller C, and Jacobs B, editors. Handbook of behavioral neuroscience. UK: Elsevier. Vol. 21, 2010. p. 203–218.
  • Guo B, Zheng C, Cai W, et al. Multifunction of Chrysin in Parkinson's model: anti-neuronal apoptosis, neuroprotection via activation of MEF2D, and inhibition of monoamine oxidase-B. J Agric Food Chem. 2016;64(26):5324–5333.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.